Publications
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
Cancers, February 2021
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFβ-expressing cancer cells in a TGFβ-dependent manner
Cellular & Molecular Immunology, January 2021
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines
OncoImmunology, September 2020
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8+ and CD4+ T-cell-mediated antitumor immunity and enhanced anti-PD1 responses
Journal for Immunotherapy of Cancer, July 2020
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
Cancer Immunology & Immunotherapy, November 2019
Peripheral memory T cells specific for Arginase-1
Cellular & Molecular Immunology, May 2019
Durable clinical responses and long-term follow-up of stage III–IV non-small-cell lung cancer (NSCLC) patients treated with IDO peptide vaccine in a phase I study - A brief research report
Frontiers in Immunology, September 2018
The T-win® technology: immune-modulating vaccines
Seminars in Immunopathology, July 2018
Immunoregulatory antigens - novel targets for cancer immunotherapy
Chinese Clinical Oncology, March 2018
The Balance Players of the Adaptive Immune System
Cancer Research, February 2018
Frequent adaptive immune responses against arginase-1
OncoImmunology, December 2017
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
OncoImmunology, August 2017
CCL22 specific T Cells: Modulating the immunosuppressive tumor microenvironment
OncoImmunology, September 2016
Anti-regulatory T cells
Seminars in Immunopathology, September 2016
Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Cytotherapy, August 2016
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Oncoimmunology, July 2016
PD-L1-specific T cells
Cancer Immunol Immunotherapy, January 2016
Novel understanding of self-reactive T cells
OncoImmunology, August 2015
Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
Journal of the National Cancer Institute, June 2015
Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer
OncoImmunology, January 2015
Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase
Clinical Cancer Research. January 2014
Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
Leukemia, January 2014
HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients
Cancer Research, March 2013
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Blood, February 2011